Leerink partners reiterated a Buy rating on the stock of MannKind Corporation on August 26, 2025.
2 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners reiterated a Buy rating on the stock of MannKind Corporation on August 26, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
MannKind Corporation
biopharmaceutical company
Related events
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.
- Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
Coverage
Newest first; wire copies grouped- Insider MonkeyLeerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now. On August 8, Le
- Insider MonkeyLeerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT MannKind Corporation (NASDAQ:MNKD) is one of the Most Oversold Penny Stocks to Buy Now. On August 6, Faisal Khurshid fro